GRI Bio shareholders reject equity plan increase by 600K shares; director David Baker elected

GRI Bio, Inc.

David Baker elected Class I director with 61,134 for vs 40,091 against (155 abstain).
Ratification of Sadler, Gibb & Associates as auditor passed: 285,641 for, 25,988 against.
Proposal to issue shares underlying warrants (Nasdaq Rule 5635(d)) passed: 51,165 for, 47,971 against.
Amendment to 2018 Equity Incentive Plan to add 600,000 shares failed: 31,556 for, 68,911 against.
Quorum of 311,668 shares (42% of eligible) present at reconvened annual meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.